

Editorial

Thrombosis and Haemostasis: Volume 100 and going strong

Klaus T. Preissner¹, Gregory Y. H. Lip²

¹Department of Biochemistry, Medical School, Justus-Liebig-University, Giessen, Germany; ²Haemostasis Thrombosis and Vascular Biology Unit, University Department of Medicine, City Hospital, Birmingham, UK

Welcome to Volume 100 of the journal! Given this landmark volume, this allows us an opportunity to reflect on where we are just now, and the direction this journal will take, at least in the near future.

We have always seen ourselves as an international journal of haemostasis, thrombosis and vascular biology, in the very broadest sense. As demonstrated in our recent 50th anniversary issue (1), the journal has evolved with the times, since its first appearance as *Thrombosis et Diathesis Haemorrhagia* in 1957. With progress in the field we have seen the content of the journal broaden in scope. Indeed, *Thrombosis and Haemostasis* has published a very wide range of highly cited papers in recent years, ranging from basic research, ex-vivo experimental models, animal models, to translational medicine, clinical trials, systematic reviews and epidemiological studies of thrombosis (2–10).

Nonetheless, basic science readers may question some of the clinical studies we publish, and *vice versa*, clinical researchers would ask for the clinical relevance of basic science research published in this journal. Clearly, the task of editing an ever broader range of manuscript topics submitted to this journal becomes ever challenging. The success of our journal is also a tribute to our hard-working Section Editors who have attempted to cover the range of topic areas. Recognising the wide range of submissions, we feel that the time was appropriate to introduce some changes with this journal, with our centenary volume [Volume 100 (July 2008)].

Firstly, we will strengthen the clinical aspects of *Thrombosis and Haemostasis* by introducing a Deputy Editor-in-Chief (Clinical Studies), and we are delighted to announce that Prof. Gregory Y. H. Lip has been appointed to this position, effective from July 1, 2008. Professor Lip is a clinical academic cardiologist with a keen interest in thrombosis and antithrombotic therapy. He is Professor of Cardiovascular Medicine at the University of Birmingham, and is based at the University Department of

Medicine, City Hospital, Birmingham, United Kingdom. He leads a large research group with wide interests ranging from wholly clinical (epidemiology, clinical trials, systematic reviews) to experimental research (cell culture, flow cytometry, etc.) but often has a ‘bench to bedside’ theme to his research, with translational medicine studies in the clinical setting. Having ‘served time’ as a Section Editor for many years for this journal, we are now delighted to welcome Professor Lip in his new role as Deputy Editor-in-Chief and look forward to a fruitful working relationship.

This change and additional clinical editorial focus, brings about some minor changes to the submission process during the online submission of manuscripts to this journal at Manuscript Central [http://mc.manuscriptcentral.com/th]. Authors will now be asked to choose either the “basic science” or “clinical studies” peer-review route, with their preferred primary handling editor, Professor Preissner (basic science) or Professor Lip (clinical studies). The allocation to Section Editors and peer review process will proceed as previously, with the same vigorous peer review process of the highest standards expected of *Thrombosis and Haemostasis*.

Furthermore, the Instructions to Authors for *Thrombosis and Haemostasis* have been updated and Original Articles should now include an extra table with two parts: (i) ‘What is known on this topic’ and (ii) ‘What this paper adds’. This table should contain two or three bullet points for each of these, with one or two short sentences for each bullet point. The objective of this table is to provide the reader with a brief, quick and focused summary of your work in the perspective of other data as well as the clinical implications, where relevant.

This volume also sees the introduction of two additional categories of submissions to this journal. Firstly, we have introduced ‘Clinical Focus’ articles which are brief overviews on clinical studies on haemostasis, thrombosis and vascular biol-

Correspondence to:

Klaus T. Preissner, PhD
Justus-Liebig-University
Department of Biochemistry, Medical School
Friedrichstrasse 24
D-35392 Giessen, Germany
Tel.: +49 641 9947550, Fax: +49 641 9947 559
E-mail: klaus.t.preissner@biochemie.med.uni-giessen.de
or
Gregory Y. H. Lip, MD
Haemostasis Thrombosis and Vascular Biology Unit
University Department of Medicine
City Hospital
Birmingham B18 7QH, England, UK
Tel.: +44 121 5075080, Fax: +44 121 554 4083
E-mail: g.y.h.lip@bham.ac.uk

Prepublished online June 11, 2008
doi:10.1160/TH08-06-0359

Thromb Haemost 2008; 100: 1–2

ogy. Secondly, we have introduced 'Pro' and 'Contra' articles debating controversies in relation to the wide field covered by *Thrombosis and Haemostasis*. Again, this volume of the journal has examples of these categories of submissions, with a 'Clinical Focus' on the thromboembolic risk associated with paroxysmal atrial fibrillation (11) and 'Pro/Contra' articles on 'Warfarin should be the drug of choice for thromboprophylaxis in elderly patients with atrial fibrillation' (12, 13). Whilst most of the submissions to these categories would be commissioned or submitted by invitation, we invite potential authors to suggest ideas to the editors for consideration. However, be careful – there is a high chance that your suggestion would be accepted and you may actually be asked to submit something, within a short deadline!

Hopefully these changes show that we continue to evolve and – despite reaching volume 100 – we are not in our twilight years, but remain very energetic, vibrant and open to new ideas. We hope that you – our readership – like these new changes to *Thrombosis and Haemostasis*, with the additional emphasis now afforded to clinical studies. Despite the latter, we must stress that basic science submissions will continue to be very welcome, as these form the building blocks of subsequent clinical research! In return, we sincerely hope you will continue to submit your very best work to us, and we promise rapid, high-quality peer review and publication, as well as a preprint online facility, with TH first. In short, *Thrombosis and Haemostasis* continues to evolve and grow – and we invite you to do so, together with us.

References

1. Preissner KT. 50 years Thrombosis and Haemostasis (1957–2007): keeping thoughts and blood in flow. *Thromb Haemost* 2007; 98: 1–2.
2. Hirsch E. Signal transduction in inflammation. Perspective clues from the leukocyte-endothelium interface. *Thromb Haemost* 2006; 95: 3–4.
3. Weitz JI. Emerging themes in the treatment of venous thromboembolism. *Thromb Haemost* 2006; 96: 239–241.
4. Schrör K, Weber AA. COX-2 inhibitors and the thrombotic risk. *Thromb Haemost* 2006; 96: 391–392.
5. Mannhalter C, Quehenberger P. Laboratory methods in the haemostatic laboratory. *Thromb Haemost* 2006; 96: 545–546.
6. Binder BR. Signaling in endothelial cells. *Thromb Haemost* 2007; 97: 334–335.
7. Görlach A. The response to cardiovascular injury: A field of emerging complexity. *Thromb Haemost* 2007; 98: 259–261.
8. Görlach A. Vascular remodelling processes: cells, signals and their integration. *Thromb Haemost* 2007; 98:919–21.
9. Herwald H. Haemostasis, vascular biology and infectious agents. *Thromb Haemost* 2007; 98: 483–484.
10. Garcia de Frutos P. Mechanisms of thrombophilia. *Thromb Haemost* 2007; 98: 485–487.
11. Lip GYH. Paroxysmal atrial fibrillation, stroke risk and thromboprophylaxis. *Thromb Haemost* 2008; 100: 11–13.
12. Mant JW. Pro: 'Warfarin should be the drug of choice for thromboprophylaxis in elderly patients with atrial fibrillation'. Why warfarin should really be the drug of choice for stroke prevention in elderly patients with atrial fibrillation. *Thromb Haemost* 2008;100: 14–15.
13. Hylek EM. Contra: 'Warfarin should be the drug of choice for thromboprophylaxis in elderly patients with atrial fibrillation'. Caveats regarding use of oral anticoagulant therapy among elderly patients with atrial fibrillation. *Thromb Haemost* 2008;100: 16–17.